Treatment of PTLD: a slow and difficult path
Author:
Affiliation:
1. Pitié-Salpêtrière Hospital, Assistance Publique–Hôpitaux de Paris, and Sorbonne Université
Publisher
American Society of Hematology
Link
https://ashpublications.org/blood/article-pdf/144/4/348/2235438/blood_bld-2024-024891-c-main.pdf
Reference9 articles.
1. Ibrutinib as part of risk-stratified treatment for posttransplant lymphoproliferative disorder: the phase 2 TIDaL trial;Chaganti;Blood,2024
2. The 5th edition of the World Health Organization classification of haematolymphoid tumours: lymphoid neoplasms;Alaggio;Leukemia,2022
3. Response to rituximab induction is a predictive marker in B-cell post-transplant lymphoproliferative disorder and allows successful stratification into rituximab or R-CHOP consolidation in an international, prospective, multicenter phase II trial;Trappe;J Clin Oncol,2017
4. Modified risk stratified sequential treatment (subcutaneous rituximab with or without chemotherapy) in B-cell posttransplant lymphoproliferative disorder (PTLD) after solid organ transplantation (SOT): the prospective multicentre phase II PTLD-2 trial;Zimmermann;Leukemia,2022
5. Randomized phase III trial of ibrutinib and rituximab plus cyclophosphamide, doxorubicin, vincristine, and prednisone in non-germinal center B-cell diffuse large B-cell lymphoma;Younes;J Clin Oncol,2019
1.学者识别学者识别
2.学术分析学术分析
3.人才评估人才评估
"同舟云学术"是以全球学者为主线，采集、加工和组织学术论文而形成的新型学术文献查询和分析系统，可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容，当前同舟云学术共收录了国内外主流学术期刊6万余种，收集的期刊论文及会议论文总量共计约1.5亿篇，并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询！咨询电话：010-8811{复制后删除}0370
www.globalauthorid.com
TOP
Copyright © 2019-2024 北京同舟云网络信息技术有限公司 京公网安备11010802033243号 京ICP备18003416号-3